Director Charles W. Newton of Keros Therapeutics, Inc. filed a Form 4 on November 19, 2026, disclosing the sale of 551 shares of common stock on November 17, 2026, pursuant to a Rule 10b5-1 trading plan.
Key Highlights
- Reporting person: Charles W. Newton, identified as a Director of Keros Therapeutics, Inc. (NASDAQ:KROS).
- First sale: 491 shares disposed of at a weighted average price of $10.83, with individual transaction prices ranging from $10.02 to $11.01 inclusive.
- Second sale: 60 shares disposed of at a weighted average price of $11.05, with individual transaction prices ranging from $11.04 to $11.06 inclusive.
- Remaining holdings: Following both transactions, Newton directly owned 11,563 shares of common stock.
- 10b5-1 plan: Both sales were made pursuant to a Rule 10b5-1 trading plan adopted by Newton on March 12, 2026.
- Transaction code: Both disposals are coded "S" (open-market sale) in the filing.
Newton's Two-Tranche Share Disposal Under Pre-Established Trading Plan
According to the Form 4 filed with the U.S. Securities and Exchange Commission, Charles W. Newton, a director of Keros Therapeutics, Inc., sold a combined 551 shares of the company's common stock on November 17, 2026. The filing identifies the transactions as direct disposals, each executed under a Rule 10b5-1 trading plan that Newton adopted on March 12, 2026.
The first tranche covered 491 shares sold at a weighted average price of $10.83 per share. The filing notes that these shares were sold in multiple transactions at prices ranging from $10.02 to $11.01 inclusive. Following that tranche, Newton's directly held position stood at 11,623 shares. The second tranche covered 60 shares sold at a weighted average price of $11.05 per share, in multiple transactions priced between $11.04 and $11.06 inclusive, bringing the remaining directly held total to 11,563 shares.
The filing states that Newton "undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price" within the respective ranges. The form was signed on November 19, 2026, by Esther Cho as Attorney-in-Fact for Newton. No derivative securities were reported in Table II of the filing.
What Was Disclosed
Director Charles W. Newton disclosed the sale of 551 total shares of Keros Therapeutics common stock on November 17, 2026, in two tranches under a pre-established 10b5-1 plan, leaving him with 11,563 directly owned shares.





Please wait processing your request...